LONDON: AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments delivered in just minutes rather…
All posts tagged AstraZeneca
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
LONDON: AstraZeneca today announced $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs contributing to the growth of the US economy. AstraZeneca’s expanding footprint in the…
AstraZeneca announces $1.5 billion investment in Singapore manufacturing
LONDON: AstraZeneca has unveiled plans to construct a state-of-the-art manufacturing facility in Singapore, dedicated to the production of antibody drug conjugates (ADCs). This $1.5 billion venture marks the company’s first foray into manufacturing within Singapore and represents a significant step in enhancing the global supply of its ADC portfolio. ADCs, which are at the forefront…
EU Panel endorses AstraZeneca’s breast cancer drug Truqap
LONDON: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca’s drug Truqap, in combination with Faslodex, for treating certain advanced breast cancer cases. The positive opinion is based on the CAPItello-291 Phase III trial results, which showed a 50% reduction in disease progression or death compared…
Angle plc signs new commercial agreement with AstraZeneca
LONDON: ANGLE plc (AIM:AGL), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE’s existing DNA damage response (“DDR”) assay for the detection of…
AstraZeneca to acquire Fusion Pharmaceuticals in a $ 2.0 billion deal
LONDON: AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. RCs…
AstraZeneca enters definitive agreement to acquire Amolyt Pharma for $1.05 billion
AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05 billion, on a cash and debt free basis.…
AstraZeneca reports strong growth in 2023 despite COVID-19 challenges
AstraZeneca, a global biopharmaceutical company, announced its financial results for the full year 2023, showing a 6% increase in total revenue and a 15% increase in core earnings per share. The company’s total revenue reached $45,811 million, up from $43,075 million in 2022, despite a decline of $3,736 million from COVID-19 medicines. Excluding COVID-19 medicines,…
AstraZeneca to buy Gracell Biotechnologies for up to $1.2bn to boost cell therapy pipeline
Acquisition of Gracell completed AstraZeneca has agreed to acquire Gracell Biotechnologies, a company developing cell therapies for cancer and autoimmune diseases, for up to $1.2bn. The deal will add GC012F, a dual-targeting CAR-T therapy for multiple myeloma, to AstraZeneca’s portfolio of cell therapies. Gracell Biotechnologies will operate as a wholly owned subsidiary of AstraZeneca, with…
AstraZeneca signs deal to acquire Icosavax Inc. for $1.1 billion
LONDON, UK: AstraZeneca has entered into a definitive agreement to acquire Icosavax Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. Under the terms of the agreement, AstraZeneca, through a subsidiary, will initiate a tender offer to acquire all of Icosavax’s outstanding…
AstraZeneca’s Truqap approved in US for advanced breast cancer
LONDON: AstraZeneca announced that its drug Truqap (capivasertib) has received approval from the US Food and Drug Administration (FDA) for the treatment of a specific type of advanced breast cancer. Truqap is a first-in-class medicine that targets the PI3K/AKT pathway, which is involved in cancer growth and resistance to therapy. Truqap is approved for use…
AstraZeneca and Cellectis partner to accelerate development of next-generation therapeutics
LONDON, UK: AstraZeneca (NYSE: AZN) today announced a collaboration and investment agreement with Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company, to accelerate the development of next-generation therapeutics in areas of high unmet need, including oncology, immunology, and rare diseases. Under the terms of the agreement, AstraZeneca will leverage Cellectis’ proprietary gene editing technologies and manufacturing…